Cannabidiol (CBD) is the second most abundant cannabinoid present in Cannabis sativa L. It is not associated with psychotropic activity and is capable to mitigate the psychotomimetic effects produced by tetrahydrocannabinol (THC). The latest cannabis decriminalization policies and the high applicability in therapeutic and technologic-industrial fields, have determined an exponential marketing growth of foods, cosmetics and in particularly medicinal products containing CBD, which are easily available for consumers. Most importantly, on 2018 United States Food and Drug Administration approved CBD oral solution with the trade name of Epidiolex® for the treatment of two rare and severe forms of epilepsy, “Lennox-Gastaut syndrome” and “Dravet syndrome”, in pediatric patients. The aim of this review was to focus on pharmacology and on legal status of CBD, to highlight the lack of harmonization of international regulatory laws over the marketing authorization of CBD-based products.
Pharmacology and legal status of cannabidiol / Brunetti, P.; Lo Faro, A. F.; Pirani, F.; Berretta, P.; Pacifici, R.; Pichini, S.; Busardo, F. P.. - In: ANNALI DELL'ISTITUTO SUPERIORE DI SANITÀ. - ISSN 0021-2571. - 56:3(2020), pp. 285-291. [10.4415/ANN_20_03_06]
Pharmacology and legal status of cannabidiol
Brunetti P.;Lo Faro A. F.;Pirani F.;Pichini S.;Busardo F. P.
2020-01-01
Abstract
Cannabidiol (CBD) is the second most abundant cannabinoid present in Cannabis sativa L. It is not associated with psychotropic activity and is capable to mitigate the psychotomimetic effects produced by tetrahydrocannabinol (THC). The latest cannabis decriminalization policies and the high applicability in therapeutic and technologic-industrial fields, have determined an exponential marketing growth of foods, cosmetics and in particularly medicinal products containing CBD, which are easily available for consumers. Most importantly, on 2018 United States Food and Drug Administration approved CBD oral solution with the trade name of Epidiolex® for the treatment of two rare and severe forms of epilepsy, “Lennox-Gastaut syndrome” and “Dravet syndrome”, in pediatric patients. The aim of this review was to focus on pharmacology and on legal status of CBD, to highlight the lack of harmonization of international regulatory laws over the marketing authorization of CBD-based products.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
